Show simple item record

dc.contributor.authorPearson, Talima
dc.contributor.authorCaporaso, J Gregory
dc.contributor.authorYellowhair, Monica
dc.contributor.authorBokulich, Nicholas A
dc.contributor.authorPadi, Megha
dc.contributor.authorRoe, Denise J
dc.contributor.authorWertheim, Betsy C
dc.contributor.authorLinhart, Mark
dc.contributor.authorMartinez, Jessica A
dc.contributor.authorBilagody, Cherae
dc.contributor.authorHornstra, Heidie
dc.contributor.authorAlberts, David S
dc.contributor.authorLance, Peter
dc.contributor.authorThompson, Patricia A
dc.date.accessioned2019-06-24T17:54:29Z
dc.date.available2019-06-24T17:54:29Z
dc.date.issued2019-02-01
dc.identifier.citationPearson, T, Caporaso, JG, Yellowhair, M, et al. Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development. Cancer Med. 2019; 8: 617– 628. https://doi.org/10.1002/cam4.1965en_US
dc.identifier.issn2045-7634
dc.identifier.pmid30652422
dc.identifier.doi10.1002/cam4.1965
dc.identifier.urihttp://hdl.handle.net/10150/633016
dc.description.abstractIt has been previously reported that ursodeoxycholic acid (UDCA), a therapeutic bile acid, reduced risk for advanced colorectal adenoma in men but not women. Interactions between the gut microbiome and fecal bile acid composition as a factor in colorectal cancer neoplasia have been postulated but evidence is limited to small cohorts and animal studies. Using banked stool samples collected as part of a phase III randomized clinical trial of UDCA for the prevention of colorectal adenomatous polyps, we compared change in the microbiome composition after a 3-year intervention in a subset of participants randomized to oral UDCA at 8-10 mg/kg of body weight per day (n = 198) or placebo (n = 203). Study participants randomized to UDCA experienced compositional changes in their microbiome that were statistically more similar to other individuals in the UDCA arm than to those in the placebo arm. This reflected a UDCA-associated shift in microbial community composition (P < 0.001), independent of sex, with no evidence of a UDCA effect on microbial richness (P > 0.05). These UDCA-associated shifts in microbial community distance metrics from baseline to end-of-study were not associated with risk of any or advanced adenoma (all P > 0.05) in men or women. Separate analyses of microbial networks revealed an overrepresentation of Faecalibacterium prausnitzii in the post-UDCA arm and an inverse relationship between F prausnitzii and Ruminococcus gnavus. In men who received UDCA, the overrepresentation of F prausnitzii and underrepresentation of R gnavus were more prominent in those with no adenoma recurrence at follow-up compared to men with recurrence. This relationship was not observed in women. Daily UDCA use modestly influences the relative abundance of microbial species in stool and affects the microbial network composition with suggestive evidence for sex-specific effects of UDCA on stool microbial community composition as a modifier of colorectal adenoma risk.en_US
dc.description.sponsorshipPartnership for Native American Cancer Prevention [NIH/NCI U54CA143924, U54CA143925]; NSF [1565100]; Biostatistics and Tissue Acquisition and Cellular/Molecular Analysis Shared Resources - NCI [P30CA023074]; [R01 CA151708]en_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1965en_US
dc.rights© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectUrsodeoxycholic aciden_US
dc.subjectbile aciden_US
dc.subjectcolorectal adenomaen_US
dc.subjectcolorectal canceren_US
dc.subjectgut microbiomeen_US
dc.titleEffects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma developmenten_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Ctr Cancen_US
dc.contributor.departmentUniv Arizona, Dept Mol & Cellular Biolen_US
dc.contributor.departmentUniv Arizona, Dept Nutr Scien_US
dc.identifier.journalCANCER MEDICINEen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleCancer medicine
refterms.dateFOA2019-06-24T17:54:29Z


Files in this item

Thumbnail
Name:
Pearson_et_al-2019-Cancer_Medi ...
Size:
2.489Mb
Format:
PDF
Description:
Final Published version

This item appears in the following Collection(s)

Show simple item record

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.
Except where otherwise noted, this item's license is described as © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.